Furthermore, the combination of Ref-1 shRNA knockdown and oxymatrine decreases A549 cellular proliferation [24], and the treatment of A549 cells with a specific Ref-1 inhibitor inhibits tumor growth and progression [24]. Here, APEX1 is linked to neoplasm.